Contrast-enhanced ultrasound in evaluating the curative effect of interventional therapy in patients with liver cancer

Table 1 Patient demographics and baseline clinical data

Factor	Statistical values
Gender (male/female)	98/26
Age (years)	56.42 ± 8.11
Body weight (kg)	68.37 ± 9.15
Height (cm)	168.62 ± 6.52
History of hypertension	40/84
History of diabetes	18/106
Smoking history	52/72
Drinking history	45/79
Family history (liver cancer)	6/118

P < 0.05 indicates a significant difference.

Table 2 Summary of tumor perfusion patterns in patients

Perfusion type	Before treatment	1 month after treatment	3 months after treatment	6 months after treatment	F value	P value
Enhanced (normal perfusion)	68.25 ± 6.23	62.75 ± 5.99	58.50 ± 5.13	53.75 ± 5.28	4.378	0.03
Uniform (low perfusion)	21.50 ± 4.56	26.50 ± 4.72	28.00 ± 4.50	31.25 ± 4.89	5.187	0.022
Non-uniform (low perfusion)	10.25 ± 3.79	10.75 ± 4.12	13.50 ± 4.12	15.00 ± 3.89	6.123	0.016
Total perfusion rate	68.25 ± 6.23	62.75 ± 5.99	58.50 ± 5.13	53.75 ± 5.28	4.378	0.03

P < 0.05 indicates a significant difference.

Table 3 Summary of tumor microvessel densities in patients

Time period	High microvascular density (%)	Low microvascular density (%)	Medium microvascular density (%)	Total (%)	F value	P value
Before treatment	72.50 ± 4.23	14.25 ± 3.65	13.25 ± 3.45	72.50 ± 4.23
1 month after treatment	60.00 ± 5.12	22.50 ± 4.43	17.50 ± 4.25	60.00 ± 5.12	5.784	0.019
3 months after treatment	50.25 ± 5.89	28.00 ± 4.95	21.75 ± 5.12	50.25 ± 5.89	7.450	0.008
6 months after treatment	40.00 ± 4.50	35.00 ± 5.45	25.00 ± 4.92	40.00 ± 4.50	9.236	0.003

P < 0.05 indicates a significant difference.

Table 4 Perfusion recovery of tumor area in patients

Time period	Complete response (%)	Partial response (%)	Stable lesions (%)	Progressive lesions (%)	χ2	P value
Before treatment	0	0	100	0
1 month after treatment	8.33	43.33	40	8.33	12.227	0.016
3 months after treatment	12.5	46.67	30	10.83	11.559	0.02
6 months after treatment	18.33	41.67	28.33	11.67	8.908	0.031

P < 0.05 indicates a significant difference.

Table 5 Enhancement response of tumor blood flow in patients

Time period	Complete disappearance of enhanced response (%)	Decrease in blood flow enhancement (%)	No change in blood flow enhancement (%)	χ2	P value
Before treatment	0	0	100
1 month after treatment	12.5	50	37.5	18.227	0.01
3 months after treatment	20.83	45.83	33.33	14.891	0.021
6 months after treatment	28.33	42.5	29.17	12.224	0.028

P < 0.05 indicates a significant difference.

Table 6 Changes of tumor markers in patients

Time period	Alpha-fetoprotein (ng/mL)	Carcinoembryonic antigen (ng/mL)	Carbohydrate antigen 19-9 (U/mL)	F value	P value
Before treatment	98.57 ± 34.89	5.24 ± 2.11	36.78 ± 14.57
1 month after treatment	56.87 ± 22.31	4.38 ± 1.94	27.36 ± 12.50	25.271	< 0.001
3 months after treatment	43.28 ± 19.12	3.78 ± 1.68	21.04 ± 10.15	23.762	< 0.001
6 months after treatment	30.91 ± 13.45	3.16 ± 1.44	18.49 ± 9.42	30.184	< 0.001

P < 0.05 indicates a significant difference.